NCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
Clinical Trials
11 trialsNCT04231851 2026-03-06
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
University of California, Irvine
Phase 2 Active not recruiting
NCT02286726 2026-03-04
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03844997 2025-05-31
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT03575325 2024-12-12
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04526288 2024-05-23
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT03335267 2024-02-22
Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia
Weill Medical College of Cornell University
Phase 2 Completed
NCT04209725 2023-12-05
A Study of CPX-351 (Vyxeosâ„¢) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT03988205 2022-07-19
Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia
Medical College of Wisconsin
Phase 4 Terminated
NCT02019069 2019-01-22
CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Stanford University
Phase 2 Completed
NCT01804101 2018-05-25
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase NA Completed